201
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation

, , , , &
Pages 185-188 | Received 30 Apr 2019, Accepted 15 Jul 2019, Published online: 07 Aug 2019
 

Disclosure statement

The clinical trial was designed solely by the investigators without input from Bristol-Myers Squibb, who also did not have any input into the analysis of results or preparation of the final manuscript. Bristol-Myers Squibb did not provide any other financial support to any of the authors.

Additional information

Funding

The work described in this manuscript pertains to a clinical trial which was funded by Bristol-Myers Squibb.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.